Skip to content

Clinical study of comprehensive therapy in the treatment of senile sensorneural hearing loss

Clinical study of comprehensive therapy in the treatment of senile sensorneural hearing loss

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005700
Enrollment
Unknown
Registered
2014-12-16
Start date
2014-12-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensorneural hearing loss

Interventions

routine acupuncture therapy group :acupuncture therapy
control group of western medicine :peroral western medicine
comprehensive therapy group :comprehensive therapy

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Non-genetic acquired sensorineural hearing loss, which conforms to the diagnosis standard; 2. Hearing loss is still in aggravated or fluctuated; 3. Age over 60, gender not limited; 4. Used no treatments, or poor treatment effect and ceased treatment for at least one week; 5. No other severe complications of systemic; or the patient has clear consciousness and can insist in cooperating with the inspection and treatment.

Exclusion criteria

Exclusion criteria: 1. Do not meet the diagnostic criteria and inclusion criteria; 2. With earring foreign object, inflammation, tumor, deformity, trauma and other diseases, diagnosed by the ear examination as conductive hearing loss, mixed hearing loss; 3. Apparent epidemic or infectious diseases occurred before the hearing loss or at present, such as herpes zoster oticus, epidemic cerebrospinal meningitis, mumps, measles, etc.; 4. Central deafness caused by the brain central lesion, which usually accompanies other dysfunctions. It can be inspected through CT or other relevant means, if necessary; 5. Diagnosed as congenital deafness, or hearing loss caused by acoustic neuroma space occupying lesions; 6. Accepting other treatments at the same time, or still being under other treatments within two weeks before the observation; 7. Patients, who can't promise to persist with the treatment or follow-up due to external reasons or individual tolerance standard.

Design outcomes

Primary

MeasureTime frame
pure tone audiometry;tinnitus;

Secondary

MeasureTime frame
clinical symptoms;

Countries

China

Contacts

Public ContactMo Wenquan
mowenquan@hotmail.com+86 13816623514

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026